Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.36 |
| ▸ | IL1B | P01584 | 4/20 | 0.36 |
| ▸ | ARF6 | P62330 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326596 | 0.88 | IL1B (0.40) | HPGDSSCN9AFPR2IL1BNLRP3 | |
| SCHEMBL29326794 | 0.85 | NLRP3 (0.41) | SCN9AFPR2IL1BARF6NLRP3 | |
| SCHEMBL29326792 | 0.82 | SCN9A (0.47) | HPGDSSCN9AFPR2IL1B | |
| SCHEMBL29326601 | 0.77 | NLRP3 (0.35) | HPGDSSCN9AFPR2IL1BNLRP3 | |
| SCHEMBL29326752 | 0.77 | KCNH2 (0.44) | IL1BHSD11B1NLRP3 | |
| SCHEMBL29326775 | 0.76 | IL1B (0.61) | HPGDSIL1BARF6SLC6A3NLRP3 | |
| SCHEMBL29326744 | 0.73 | CDK4 (0.38) | IL1B | |
| SCHEMBL29326781 | 0.73 | IL1B (0.43) | IL1BSLC6A3NLRP3 | |
| SCHEMBL29326501 | 0.73 | NLRP3 (0.49) | SCN9AFPR2IL1BNLRP3 | |
| SCHEMBL29326100 | 0.71 | HSD11B1 (0.37) | HPGDSSCN9AHSD11B1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | HPGDS 3900/4885SCN9A 3093/4885FPR2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.